GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...
Hosted on MSN13h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
GlobalData on MSN20h
Alphamab doses first subject in trial of JSKN003 for ovarian cancerAlphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
General and Administration (G&A) expenses for the three months ended December 31, 2024 were $3.6 million USD, compared to $5.3 million USD for the same period in 2023. The decrease was primarily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback